Cargando...
Hypoxia‐inducible factor‐targeting prodrug TOP3 combined with gemcitabine or TS‐1 improves pancreatic cancer survival in an orthotopic model
Pancreatic cancer is one of the most lethal digestive system cancers with a 5‐year survival rate of 4–7%. Despite extensive efforts, recent chemotherapeutic regimens have provided only limited benefits to pancreatic cancer patients. Gemcitabine and TS‐1, the current standard‐of‐care chemotherapeutic...
Guardado en:
| Publicado en: | Cancer Sci |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
John Wiley and Sons Inc.
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4982586/ https://ncbi.nlm.nih.gov/pubmed/27270607 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12982 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|